PPARA and metabolic dysfunction-associated steatotic liver disease: Given the limited amount of literature focusing on the connection between PPAR-α, FGF-19, and butanoate metabolism, it is suggested that butyrate can upregulate PPAR-α in hepatocytes, thereby alleviating HFD-induced MASLD in rats through the activation of β-oxidation and inflammation suppression 71.